Softgel Source, LLC announced a new program for rapid turnaround of low-volume, custom ingestible softgels, offering production priority and no minimum order quantity to facilitate product testing. The initiative aims to support U.S. companies in bringing manufacturing back home and strengthening their competitive position in the marketplace. Kevin McDowell, Founder and CEO of Softgel Source, stated that U.S. companies face both challenges and opportunities in domestic manufacturing. The company's Portland location positions it to help biotech and pharmaceutical businesses rapidly develop and test new softgel products.
This expansion reflects broader trends in U.S. manufacturing, with Deloitte and The Manufacturing Institute projecting continued job growth and biotech manufacturing expected to grow 6–8% annually through 2030. Businesses dependent on offshore manufacturing increasingly face disrupted supply chains, long lead times, and shifting tariffs. McDowell emphasized that manufacturers investing in domestic product development will be best positioned to thrive. Softgel Source helps companies address these issues by offering U.S.-manufactured softgels with fast turnaround rates, serving as both a primary development partner and backup production source when offshore suppliers falter.
The program also addresses regulatory challenges, as constant changes in U.S. and international regulations require companies to reformulate and retest products on short notice. McDowell noted that a local U.S. manufacturer with fast turnaround and low minimum order quantities is ideal for time-sensitive reformulation and testing requirements. More information about the company's services is available at https://softgelsource.com.
Softgel Source focuses on custom softgel manufacturing for vitamin, medication, supplement, and pet product industries, specializing in responsive, rapid turnaround of prototype production and low-to-moderate volume manufacturing for U.S.-based clients. The company's approach supports the growing movement toward domestic manufacturing resilience and regulatory compliance in the ingestible products sector. This development matters because it provides a practical solution for companies navigating complex global supply chains while meeting stringent regulatory requirements, potentially accelerating innovation and reducing dependency on overseas production.
